Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice

Didier Cataldo, Eric Derom, Giuseppe Liistro, Eric Marchand, Vincent Ninane, Rudi Peché, Hans Slabbynck, Walter Vincken, Wim Janssens

Onderzoeksoutput: Scientific review

20 Citaten (Scopus)

Samenvatting

Evidence and guidelines are becoming increasingly clear about imbalance between the risks and benefits of inhaled corticosteroids (ICSs) in patients with COPD. While selected patients may benefit from ICS-containing regimens, ICSs are often inappropriately prescribed with - according to Belgian market research data - up to 70% of patients in current practice receiving ICSs, usually as a fixed combination with a long-acting β2-adrenoreceptor agonist. Studies and recommendations support withdrawal of ICSs in a large group of patients with COPD. However, historical habits appear difficult to change even in the light of recent scientific evidence. We have built a collaborative educational platform with chest physicians and primary care physicians to increase awareness and provide guidance and support in this matter.

Originele taal-2English
Pagina's (van-tot)2089-2099
Aantal pagina's11
TijdschriftInternational Journal of Chronic Obstructive Pulmonary Disease
Volume13
DOI's
StatusPublished - 2018

Vingerafdruk

Duik in de onderzoeksthema's van 'Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice'. Samen vormen ze een unieke vingerafdruk.

Citeer dit